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Abstract Experimental partial hepatectomy of more than 80% of the liver weight bears an increased mortality in rodents,
due to impaired hepatic regeneration in small-for-size liver remnants. Granulocyte colony-stimulating factor (G-CSF)
promotes progenitor cell expansion and mobilization and also has immunomodulatory properties. The aim of this study was
to determine the effect of systemically administered G-CSF on liver regeneration and animal survival in a small-for-size
liver remnant mouse model. Mice were preconditioned daily for 5 days with subcutaneous injections of 5 μg G-CSF or aqua
ad injectabile. Subsequently, 83% partial hepatectomy was performed by resecting the median, the left, the caudate, and the
right inferior hepatic lobes in all animals. Daily sham or G-CSF injection was continued. Survival was significantly better in
G-CSF-treated animals (P<0.0001). At 36 and 48 h after microsurgical hepatic resection, markers of hepatic proliferation
(Ki67, BrdU) were elevated in G-CSF-treated mice compared to sham injected control animals (P<0.0001) and dry liver
weight was increased (P<0.05). G-CSF conditioning might prove to be useful in patients with small-for-size liver remnants
after extended hepatic resections due to primary or secondary liver tumors or in the setting of split liver transplantation.
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Introduction
Intense regeneration and almost 100% survival follows
partial hepatectomy (PH) of 70% of liver mass in rodents.1–3
More extensive resections of 70 to 85% PH bear increased
mortality due to impaired liver regeneration and the
development of acute hepatic failure.4–7
Similarly, the human liver regenerates after hepatic
resection. The size of the remaining liver tissue after
resection is crucial for successful restoration of liver mass.
In humans, a liver remnant of 45%, corresponding to at least
1.2% of body weight, results in excellent regeneration and
uncomplicated recovery.8 More extensive resections (i.e.,
50 to 70% resections) with smaller liver remnants can
cause impaired regeneration and subsequent hepatic failure.
Therefore, 0.8% of body weight is currently considered the
minimal weight of the liver remnant in patients undergoing
hepatic resection.8–11
While liver regeneration after partial hepatectomy is a
well-characterized phenomenon, the reasons for impaired
regeneration in small-for-size liver remnants (i.e., <0.8% of
body weight) are far from being understood.3,12,13 Recently
identified bone marrow-derived adult liver progenitor cells
might play an important role in the pathophysiology of
impaired liver regeneration.14,15
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Granulocyte colony-stimulating factor (G-CSF) pro-
motes proliferation and mobilization of the bone marrow
progenitor cell population.16–18 Furthermore, G-CSF has
antiinflammatory and antiinfectious effects.16,19 Clinical
data in humans indicate that G-CSF administration provides
hepatic support during acute liver failure and is also
beneficial after major surgical interventions.19,20
In rodent models of toxic liver injury, G-CSF accelerated
recovery and improved animal survival.21–23 From a
surgical point of view, the support of hepatic recovery after
extended liver resection is of crucial importance.10,24 We
hypothesized that G-CSF could provide such support in an
experimental setting. Using a microsurgical small-for-size
liver remnant mouse model (remnant liver weight below
0.8% of mouse body weight), we determined the effects of
G-CSF on animal survival, on the number of nucleated
bone marrow cells, and on hepatic regeneration.
Material and Methods
Adult male BalbC mice (n=102, 20–25 g, 6–8 weeks) were
kept under standard conditions. All animal experimentation
was approved by the local committee for animal welfare in
accordance with the European Convention on Animal Care.
Surgeries were performed as previously described.25
Experimental Groups
Animals were stratified in a G-CSF (n=53) and a sham-
conditioned group (n=49). G-CSF animals received a daily
subcutaneous injection of 5 μg G-CSF in 100 μl of aqua ad
injectabile (Granocyte®, Aventis Pharma AG, Zurich,
Switzerland) for 5 days preoperatively and daily after liver
resection until the end of the experiment. Sham controls
were injected daily with 100 μl of aqua ad injectabile.
Surgical Procedures
From a microsurgical point of view, the mouse liver
consists of five lobes. For male adult BalbC mice, the
relative weight of each liver lobe as a percent of the whole
is known: the left lobe=34%, the median lobe=26%, the
right superior lobe=17%, the right inferior lobe=15%, and
the caudate lobe=8%.25 For the 83% PH, the lesser
omentum was incised and the caudate lobe resected. After
incision of the left triangular and the falciform ligament, the
left and the median lobes were resected. The pedicle of the
right inferior lobe was exposed by incision of the ligament
between the vena cava posterior and the anterior liver
capsule. The pedicle of the right inferior lobe was then
carefully ligated and the right inferior lobe excised.7 The
resected liver tissue and the entire mouse were weighed.
Animals were kept under a warming lamp for 24 h
postoperatively. To prevent postoperative hypoglycemia,
1.0 ml of 5% glucose (Bioren SA, Couvet, Switzerland)
was injected subcutaneously.6,26 Daily subcutaneous G-
CSF and sham conditioning were continued.
Tissue Harvest
The regenerating liver was examined 36 and 48 h after
83% PH in 20 animals. 5-bromo-2’-deoxyuridine (BrdU,
50 mg/kg body weight, Fluka Biochemica, Buchs, Switzer-
land) was injected intraperitoneally 2 h before liver
harvesting. Under inhalation anesthesia, animals were then
killed and the remnant right superior liver lobe excised,
weighed, and fixed in 4% formalin (Sigma, Buchs,
Switzerland). Dry liver weight was determined 72 h after
65°C heat exposure. Tissue from the duodenum and testis
served as positive controls for BrdU incorporation.
Immunohistochemistry (Ki67 Expression,
BrdU Incorporation)
To measure hepatic proliferation, the expression of Ki67
and BrdU incorporation were determined in the right
superior liver lobe at 36 and 48 h after 83% PH on
paraffin-embedded tissue sections as described.7 Briefly,
before Ki67 staining, 2–3 μm paraffin-embedded sections
were dewaxed, rehydrated, and pretreated by boiling in
10 mM citrate buffer, pH 6.0, in a pressure cooker. Sections
were then washed in Tris-buffered saline (TBS) and
incubated with a rat anti-mouse Ki67 antibody (clone
TEC-3; Dako, Glostrup, Denmark) diluted 1:200 in TBS
with 0.5% casein and 5% normal goat serum for 60 min at
room temperature. Next, a 1:300 dilution of a biotinylated
goat anti-mouse immunoglobulin antiserum (DakoCytoma-
tion, Glostrup, Denmark) was applied for 45 min. Thereafter,
sections were incubated with an avidin–biotin-complex/
horseradish peroxidase system (1:100 in TBS, Vector,
Burlingame CA, USA) for 45 min. Finally, sections were
developed in 0.1% 3,30-diaminobenzidine (Sigma, St. Louis
MO, USA) with 0.03% H2O2, counterstained with hema-
toxylin, and mounted. Ki67 positive and negative nuclei
were counted in 10 high-power field microscopy images by
two independent researchers, and the Ki67 labeling index
was calculated from the data obtained.27
After BrdU staining,7 BrdU positive cells in duodenal
crypts and testis demonstrated systemic BrdU uptake and
nuclear incorporation. Liver samples not treated with the
primary anti-BrdU antibody served as negative controls.
BrdU positive and negative cells were counted and the
BrdU labeling index was calculated as described.7
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Cell Isolation from the Adult Mouse Bone Marrow
and Magnetic Cell Sorting of β2-Microglobulin Negative/
Thy-1 Positive Progenitor Cells
Femoral bone marrow cells were harvested by aspiration
through a 23-gauge needle (Venflon, Becton Dickinson,
Fraga, Spain) as described,28 filtered through a 30 μm
filter (Nr. 130-041-407, Myltenyi Biotech, Bergisch Glad-
bach, Germany), and counted. To determine the amount of
adult bone marrow-derived liver progenitor cells, β2-
microglobulin negative/Thy-1 positive cells were isolated
according to a recently developed magnetic cell-sorting
protocol and counted using a Neubauer counting chamber
in a blinded fashion.15,29
Statistical Analysis
Results are expressed as mean ± standard deviation.
Cumulative survival was analyzed according to Kaplan–
Meier and survival curves compared by the use of the log-
rank test. For normally distributed data, Student’s t test was
applied (Jandel Scientific 1.0, San Rafael, CA, USA), and
for nonnormally distributed data the Mann–Whitney rank
sum test was used. The significance level was set at P<0.05.
Results
The Small-for-size Liver Remnant Model (83% PH)
in the Mouse
The amount of liver tissue resected corresponded to 3.8±
0.4% of mouse body weight in the sham-conditioned
group and was not different in the G-CSF-conditioned
group (3.9±0.3% of body weight, t test: P=0.54).
Cumulative Survival
The cumulative survival was determined according to
Kaplan–Meier in G-CSF-conditioned (n=35) and in sham-
conditioned animals (n=33). The survival curve is depicted
in Fig. 1. By postoperative day 3 all animals of the sham-
conditioned group were dead. G-CSF-conditioned animals
survived significantly better (25.7% on day 7 and thereafter,
log rank test: P<0.0001). A total of nine G-CSF-
conditioned animals were censored 14 days after 83% PH.
Dry Liver Weight
Dry liver weight was significantly increased in G-CSF-
conditioned mice (0.475±0.050% of body weight) when com-
pared to sham-treated control animals (0.325±0.096% of body
weight, t test: P<0.05) 36 h after 83% partial hepatectomy.
Markers of Liver Regeneration (Ki67 Expression
and BrdU Incorporation)
Ki67 expression in hepatocytes was elevated in the G-CSF
group at 36 h (2.8±2.6 vs 0.03±0.2%, rank sum test: P<
0.0001) and at 48 h (45.1±34.6 vs 0.7±1.0%, rank sum
test: P<0.0001) after 83% PH. BrdU labeling of hepato-
cytes at 48 h was 0.1±0.3% in the sham and 35.2±34.2%
in the G-CSF group (rank sum test: P<0.0001; Fig. 2). No
zone-specific BrdU-positive cell clusters were seen.
Isolation of Nucleated Cells from the Adult Bone Marrow
The total nucleated cell count of the adult femoral mouse
bone marrow was 9:5 0:8 106 cells (n=3 for each ex-
perimental group and each time point) in sham-conditioned
animals before hepatic resection, and significantly lower at
6:9 0:1 106 cells 24 h after 83% PH (P<0.05).
After 5 days of G-CSF preconditioning, 8:5 1:7 106
nucleated cells were present in the bone marrow (P=ns
when compared to sham-conditioned control animals). At
24 h after 83% resection, the total number of nucleated cells
rose significantly during hepatic regeneration in G-CSF-
conditioned animals, to 13:4 1:4 106 cells (P<0.05
when compared to preoperative values, and P<0.05 when
compared to bone marrow cell numbers in sham-conditioned
mice 24 h after 83% PH).
Adult liver progenitor cells were purified by β2-micro-
globulin negative and Thy-1 positive magnetic cell sorting.
In sham-conditioned animals, 6.3±0.8% were identified
before and 7.5±5.8% after 83% PH as β2-microglobulin
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Figure 1 Cumulative survival (according to Kaplan–Meier) in G-
CSF-conditioned mice and sham-treated control animals after 83%
partial hepatectomy. Survival after extended 83% hepatic resection in
mice was significantly better with granulocyte colony stimulating
factor (G-CSF) conditioning. No sham-conditioned animals survived
longer than 72 h after 83% partial hepatectomy, while 25.7% survival
was observed in the G-CSF-conditioned group.
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negative/Thy-1 positive (P=ns). In G-CSF-conditioned
animals, 5.4±4.3% of bone marrow cells were β2-micro-
globulin negative/Thy-1 positive before resection and 5.8±
2.1% were β2-microglobulin negative/Thy-1 positive after
83% PH (P=ns).
Discussion
The microsurgical 83% PH mouse model is suitable for
testing hepatic supportive regimens in the experimental
setting of small-for-size liver remnants. Control mice
showed impaired liver regeneration, hepatic encephalopa-
thy, and consequent death within 3 days after 83% PH, as
expected.6,13,26
In contrast, 25.7% of G-CSF-conditioned mice survived.
Dry liver weight was significantly increased, and expres-
sion of the immunohistochemically measured markers of
proliferation was significantly higher in the G-CSF group.
For clinical use, the described systemic G-CSF condi-
tioning could under certain conditions allow more radical
resections for primary or secondary liver tumors and
support the small-for-size liver remnant during hepatic
regeneration. This support could also be helpful in the
setting of living related liver donation. Currently, a right
hemihepatectomy is performed for adult living related liver
donation and consequently around 65% of the liver is
grafted.30 The remaining 35% of the left liver should allow
safe and uncomplicated hepatic regeneration for the donor.
However, due to technical difficulties when performing
right hemihepatectomies, including multiple anatomic
variants of the portal triad and the hepatic veins or due to
impaired hepatic regeneration, a 0.5% mortality is reported
after living related liver donation in the donor population.30
Due to limitations in the ratio of graft liver weight to
recipient body weight, living donor liver transplantation of
the left lateral segments II and IIl is so far mainly
established in pediatric recipients. From the surgical point
of view, this procedure is significantly safer than a right
hemihepatectomy for the donor.31 When the regenerative
capacity of small split liver grafts could be augmented (i.e.,
by the use of G-CSF preconditioning), segmental liver
transplantation from both cadaveric and living donors could
be safely proposed for adult recipients as well.
On the other hand, the administration of growth factors
to patients suffering from carcinomatous disease has to be
critically assessed. Fortunately, 15 years of clinical experi-
ence have provided no convincing evidence that G-CSF
causes malignant transformation or worsens the course of
malignant disease.32,33
A distinct progenitor cell population was recently
successfully isolated from adult rodent bone marrow by
our group.15,28,29 We expected that G-CSF might expand,
activate, and mobilize the described β2-microglobulin
negative/Thy-1 positive bone marrow progenitor cells
during regeneration of the small-for-size liver remnant.
Nucleated bone marrow cells were therefore monitored
before and after 83% PH. As expected, the total nucleated
cell count was significantly elevated after 6 days of G-CSF
conditioning.18 But to our surprise, no alteration of the β2-
microglobulin negative/Thy-1 positive progenitor cell pool
was detectable after 83% PH in either experimental group
by the magnetic cell sorting procedure used. Furthermore, a
typical pattern of progenitor cell support was not seen in the
Figure 2 BrdU staining 48 h after 83% partial hepatectomy. While no
BrdU positive cells were detectable in the sham-conditioned group,
active liver regeneration, and positive BrdU staining were seen in G-
CSF-treated animals. Duodenal tissue (a) served as an internal control
to ascertain adequate BrdU uptake and incorporation. Liver samples
after 70% partial hepatectomy served as positive (b) and negative (no
primary antibody, c) controls.
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G-CSF-conditioned regenerating liver samples and homo-
geneously distributed BrdU as well as Ki67 positive hepatic
nuclei were found in the entire mouse liver lobes.15,34 It is,
however, possible that bone marrow progenitor cells
supported liver regeneration by direct fusion, as de-
scribed.35 On the other hand, the observed G-CSF effect
might be directly related to its recognized immunomodula-
tory properties and possibly improved neutrophil func-
tion,19,20 thereby preventing typical systemic septic
complications during the clinical course after extended
liver resection.8
Conclusion
G-CSF supports liver regeneration and promotes survival in
a small-for-size liver remnant mouse model. Additional
human studies might prove that systemic G-CSF condi-
tioning could be clinically valuable for the treatment of
patients after major hepatic resections or in the setting of
split liver transplantation.
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